Literature DB >> 8928836

Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.

L Jetté1, E Beaulieu, J M Leclerc, R Béliveau.   

Abstract

To see whether P-glycoprotein (PGP) expressed in renal brush-border membranes (BBM) could interact with compounds known as modulators of multidrug resistance (MDR), photoaffinity-labeling experiments were performed. A 145k-Da protein was photolabeled with [125I] iodoarylazidoprazosin, and this labeling was reduced in the presence of cyclosporin A (CsA) and PSC-833 (PSC). Interaction of CsA with PGP was further investigated by treating rats with daily subcutaneous injections of CsA (10 mg.kg-1.day-1). After this treatment, PGP expression levels were dramatically increased in renal BBM, intestine, liver, and many other tissues except the brain. This induction was a reversible process, since after cessation of CsA administration PGP levels declined to reach values similar to those of the control groups. The increase in PGP expression in the kidney was also detected in photolabeling experiments, suggesting the induction of a functional PGP. A higher dose of CsA (50 mg/kg) given as a bolus injection did not modify PGP expression] in renal BBM. These results demonstrate that CsA induces reversible overexpression of PGP in the rat. This may present significant relevance in the design of clinical trials using CsA as a chemosensitizing agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8928836     DOI: 10.1152/ajprenal.1996.270.5.F756

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

Review 1.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats.

Authors:  S Yasumiba; S Tazuma; H Ochi; K Chayama; G Kajiyama
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 3.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

4.  Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.

Authors:  R G del Moral; M Andujar; C Ramírez; M Gómez-Morales; M Masseroli; M Aguilar; A Olmo; F Arrebola; M Guillén; M J García-Chicano; F F Nogales; F O'Valle
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

5.  Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Authors:  Andaleeb Sajid; Natarajan Raju; Sabrina Lusvarghi; Shahrooz Vahedi; Rolf E Swenson; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

6.  Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates.

Authors:  Run Tian; Noriko Koyabu; Hitomi Takanaga; Hirotami Matsuo; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells.

Authors:  Naoki Nishio; Toshiya Katsura; Ken-ichi Inui
Journal:  Pharm Res       Date:  2007-11-15       Impact factor: 4.200

Review 8.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

9.  Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2007-09       Impact factor: 3.534

10.  Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells.

Authors:  Yan-Gang Zhou; Kun-Yan Li; Huan-De Li
Journal:  Eur J Clin Pharmacol       Date:  2008-05-14       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.